

1 **Phosphatidylserine within the Viral Membrane Enhances Chikungunya Virus Infectivity in**
2 **a Cell-type Dependent Manner**

3 Kerri L. Miazgowicz¹, Judith Mary Reyes Ballista¹, Marissa D. Acciani¹, Ariana R. Jimenez¹,
4 Ryan S. Belloli¹, Avery M. Duncan¹, Katherine E. Havranek¹, and Melinda A. Brindley^{1,2#}

5 ¹Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia,
6 Athens, Georgia, USA

7 ²Department of Infectious Diseases, Department of Population Health, College of Veterinary
8 Medicine, University of Georgia, Athens, Georgia, USA

9

10 #Corresponding author: mbrindle@uga.edu

11

12 Abstract word count: 246

13 Text word count:9960

14 **Abstract**

15 Chikungunya virus (CHIKV), an alphavirus of the *Togaviridae* family, is the causative
16 agent of the human disease chikungunya fever (CHIKF), which is characterized by debilitating
17 acute and chronic arthralgia. No licensed vaccines or antivirals exist for CHIKV. Preventing the
18 attachment of viral particles to host cells is an attractive intervention strategy. Viral entry of
19 enveloped viruses from diverse families including *Filoviridae* and *Flaviviridae* is mediated or
20 enhanced by phosphatidylserine receptors (PSRs). PSRs facilitate the attachment of enveloped
21 viruses to cells by binding to exposed phosphatidylserine (PS) in the viral lipid membrane - a
22 process termed viral apoptotic mimicry. To investigate the role of viral apoptotic mimicry during
23 CHIKV infection, we produced viral particles with discrete amounts of exposed PS on the virion
24 envelope by exploiting the cellular distribution of phospholipids at the plasma membrane. We
25 found that CHIKV particles containing high outer leaflet PS (produced in cells lacking flippase
26 activity) were more infectious in Vero cells than particles containing low levels of outer leaflet
27 PS (produced in cells lacking scramblase activity). However, the same viral particles were
28 similarly infectious in NIH3T3 and HAP1 cells, suggesting PS levels can influence infectivity
29 only in cells with high levels of PSRs. Interestingly, PS-dependent CHIKV entry was observed
30 in mosquito Aag2 cells, but not C6/36 cells. These data demonstrate that CHIKV entry via viral
31 apoptotic mimicry is cell-type dependent. Furthermore, viral apoptotic mimicry has a
32 mechanistic basis to influence viral dynamics *in vivo* in both the human and mosquito host.

33 **Importance**

34 Outbreaks of Chikungunya virus (CHIKV) have occurred throughout Africa, Asia, and
35 Europe. Climate change permits the expansion of *Aedes* mosquito vectors into more temperate
36 regions, broadening the geographic range and increasing the frequency of future human
37 outbreaks. The molecular basis underlying the broad host and cellular tropism of CHIKV
38 remains unresolved. While several host molecules have been implicated in CHIKV viral
39 attachment and entry, the role of lipid-mediated attachment (viral apoptotic mimicry) is unclear.
40 We observed that higher levels of externalized phosphatidylserine (PS) in the viral lipid bilayer
41 correlated with enhanced CHIKV infectivity in mammalian cells abundant with PS receptors and
42 lacking alternative attachment factors. Interestingly, CHIKV infection in mosquito Aag2 cells
43 was also affected by viral PS accessibility. This study further delineates the role of virus-cell
44 attachment molecules in CHIKV infection. Viral apoptotic mimicry has potential to influence
45 CHIKV dynamics *in vivo* in both the human and mosquito host.

46 **Introduction**

47 Chikungunya virus (CHIKV) is the causative agent of the human disease chikungunya
48 fever (CHIKF). CHIKF develops in approximately 82-95% of infected individuals (1, 2), and is
49 often characterized by debilitating arthralgia in the joints which becomes chronic in 12-36% of
50 cases (3, 4). Other common symptoms include rash, fever, headache and in extreme but rare
51 cases, death (5). Currently, there are no licensed vaccines or antivirals specific to CHIKV.
52 Humans acquire CHIKV from the bite of infected *Aedes aegypti* or *Aedes albopictus* mosquitoes
53 (6, 7). CHIKV outbreaks were originally limited to Africa or Asia (8, 9), however, modern
54 outbreaks introduced CHIKV throughout the Americas and Europe (10-12). The expansion of
55 mosquito vectors (e.g., *Aedes albopictus*) to temperate regions increases the likelihood of future
56 CHIKV outbreaks. Vector control remains the most effective strategy to limit the spread of
57 CHIKV (12-15). Developing interventions that interrupt transmission is essential to mitigating
58 the global health burden from CHIKF.

59 CHIKV is an *Alphavirus* within the *Togaviridae* family. CHIKV has a positive-sense
60 single-stranded RNA genome that encodes four non-structural proteins (nsP1-4) and six
61 structural proteins (capsid, E1, E2, E3, 6K and TF) (16, 17). CHIKV virions are enveloped,
62 icosahedral particles, studded with 80 glycoprotein spikes comprised of trimeric E1/E2
63 heterodimers (18, 19). E2 is associated with cellular attachment (16) and E1 is a class II fusion
64 protein that mediates membrane fusion after internalization (16, 20). After capsid uncoating and
65 genome release, genome replication complexes are formed in cytoplasmic invaginations at the
66 plasma membrane (PM), which serve as the site of particle assembly and budding (21).

67 Virus-cell attachment is an essential step in viral invasion of the host cell. Matrix
68 remodeling associated 8 (MXRA8) (22), glycosaminoglycans (GAGs) such as heparan sulfate

69 (HS) (23-26), C-type lectins including DC-SIGN (27, 28), prohibitin 1 (PHB-1) (29) and
70 phosphatidylserine (PS) receptors such as TIM-1 (30-32) or CD300a (33) have all been
71 implicated in promoting CHIKV entry. The role of MXRA8 in CHIKV pathogenesis has recently
72 been investigated *in vivo* (22, 34). While MXRA8-deficient mice did not develop joint
73 inflammation, infectious virus was still detected in peripheral tissues during acute infection (34),
74 supporting the notion that alternative surface molecules are involved in mediating viral
75 establishment and dissemination. However, none of the identified binding partners are essential
76 to CHIKV infection. Thus, the broad host and cellular tropism of CHIKV may stem from its
77 ability to bind a multitude of molecules present on the cellular surface as opposed to a single
78 ubiquitous factor.

79 PS on the cell exterior provides a diverse array of physiological functions including cell
80 signaling and membrane fluidity (reviewed in (35)). As such, cells strongly regulate PS
81 orientation within the plasma membrane (PM) to prevent the premature display of PS on the
82 exterior of the cell by restricting PS to the cytosolic leaflet (36). Type 4 P-type ATPases (P4-
83 ATPases), termed flippases, actively translocate PS from the exoplasmic leaflet of the lipid
84 bilayer to the cytosolic leaflet in an ATP-dependent manner to maintain an asymmetric PS
85 gradient in healthy cells (37, 38). P4-ATPases require a subunit from the CDC50 family to
86 promote appropriate cellular localization and flippase activity (39-41). Apoptotic induction
87 results in the irreversible inactivation of P4-ATPases through caspase cleavage (42), and
88 activation of a second class of phospholipid regulatory enzymes, termed scramblases (43).
89 Scramblases indiscriminately shuffle phospholipids between the inner and outer leaflets (43).
90 Some scramblases, including transmembrane protein 16F (TMEM16F), can undergo a reversible

91 activation through calcium signaling (44), while others, such as XK-related protein 8 (XKR8),
92 are irreversibly activated from caspase cleavage after apoptotic initiation (43).

93 Phosphatidylserine receptors (PSRs) can facilitate pathogen attachment to cells (30, 31,
94 45-48). The induction of cellular apoptosis after viral infection was traditionally considered a
95 host-driven antiviral response. However, mounting evidence from several viral families
96 including *Filoviridae* (e.g. Ebola virus (31, 49)) and *Flaviviridae* (e.g. Dengue virus (30, 33, 50))
97 illustrates that virions budding from an apoptotic cell can confer pro-viral effects. Viruses
98 containing outer-leaflet associated PS in the viral envelope can engage PSRs on host cells,
99 mimicking apoptotic bodies and triggering internalization (51). As CHIKV buds from the PM of
100 an infected cell, PS externalization during apoptosis could enhance the ability of virions to attach
101 to nearby uninfected cells.

102 In this study, we exploited PM-associated flippases and scramblases to modify the natural
103 phospholipid dynamics within the lipid bilayer of the cellular PM to produce CHIKV virions
104 with distinct levels of external PS (low, moderate, or high). We used these particles to assess the
105 role of viral apoptotic mimicry during CHIKV infection. We postulated that increased PS levels
106 in the outer leaflet of the virion envelope would promote cellular attachment, resulting in a more
107 efficient infection in cells containing PSRs. Understanding the variation in entry efficiency
108 among CHIKV attachment factors broadens our understanding of the molecular basis for the
109 diverse species and tissue tropism of CHIKV. Viral dynamics and the cross-species transmission
110 of CHIKV between mammalian and mosquito hosts are likely influenced by the assortment of
111 cellular attachment factors across cell types.

112

113 **Results**

114 ***TIM-1 enhances CHIKV infection in a cell-dependent manner***

115 Previous studies demonstrated that CHIKV infection could be enhanced by the addition
116 of entry factors including MXRA8, lectin binding proteins, and phosphatidylserine receptors (31,
117 32, 45). First, we sought to confirm previous findings in 293T cells and evaluate if an infection
118 enhancement is observed in commonly used cell lines including HAP1 and Vero cells. Cells
119 were transfected with a plasmid encoding hTIM-1 fused with GFP (hTIM-1-GFP), MXRA8, L-
120 SIGN or a control GFP plasmid. Production of exogenous hTIM-1-GFP, MXRA8, or L-SIGN in
121 293T cells, which do not natively produce these proteins (22, 31, 52), was verified by flow
122 cytometry (**Figure 1A**). We then assessed transfected cells (GFP⁺) for CHIKV infection
123 (mKate⁺) in comparison to GFP-only control wells. Corroborating previous studies (31, 32, 45),
124 the production of hTIM-1-GFP resulted in a 4-fold increase in CHIKV infection in 293T cells
125 relative to GFP-only transfected cells (**Figure 1B**). However, production of exogenous TIM-1-
126 GFP did not increase CHIKV entry into HAP1 or Vero-hSLAM (VeroS) cells (**Figure 1C, D**).
127 CHIKV more readily infected 293T and HAP cells producing MXRA8 (**Figure 1B, C**). Yet,
128 production of MXRA8 did not enhance CHIKV entry into VeroS cells (**Figure 1D**). L-SIGN
129 addition resulted in a 5-fold increase in CHIKV infection in 293T cells but had no effect on
130 HAP1 or VeroS cells (**Figure 1B-D**). Overproduction of individual CHIKV attachment factors
131 facilitated CHIKV infection in a cell-type dependent manner.

132 To confirm that the infection enhancements were specific to CHIKV, we infected cells
133 producing exogenous entry factors with recombinant vesicular stomatitis virus (rVSV)
134 containing the Lassa virus glycoprotein (rVSVΔG/LASV) (52). Both 293T and HAP1 cells
135 produce properly glycosylated alpha-dystroglycan, the high affinity receptor for Lassa virus (53,
136 54), whereas VeroS cells do not (47, 55). As expected, the overproduction of TIM-1, MXRA8,

137 or L-SIGN did not significantly affect the entry of rVSV Δ G/LASV into either 293T, HAP1, or
138 VeroS cells (**Figure 1E-G**).

139 Lastly, we used rVSV particles containing the Ebola virus glycoprotein
140 (rVSV Δ G/EBOV), which has previously demonstrated a viral enhancement with
141 phosphatidylserine receptors, but not with CHIKV-specific receptor MXRA8. Entry of
142 rVSV Δ G/EBOV particles (49) was enhanced in 293T cells producing TIM-1 (**Figure 1H**). As
143 expected, MXRA8 did not increase rVSV Δ G/EBOV infection in 293T, HAP1, or VeroS cells
144 (**Figure 1H-J**). L-SIGN enhanced rVSV Δ G/EBOV infection by 8-fold in 293T cells and by 3.5-
145 fold in HAP1 cells but had no effect in VeroS cells (**Figure 1H-J**). Together, these data suggest
146 that the role of viral apoptotic mimicry in infection is cell-type specific and depends on the
147 receptors and attachment factors present on the cellular surface.

148 *Flippase and scramblase knockout cells alter natural PS externalization*

149 To further evaluate the role of PS and PSRs in CHIKV infection, we used cells with
150 modified PS translocation dynamics at the plasma membrane (PM) to generate CHIKV virions
151 with discrete levels of exposed PS on the viral envelope. Knocking out (KO) CDC50A in HAP1
152 cells (HAP1 Δ CDC50A) eliminates P4-ATPase flippase activity, theoretically resulting in cells
153 with relatively high PS levels in the outer leaflet of the PM. In contrast, deleting XKR8 in HAP1
154 cells (HAP1 Δ XKR8) prevents apoptosis-induced scramblase activity, theoretically resulting in
155 cells with outer leaflets that remain low in PS even during apoptosis.

156 Flippase and scramblase knockout lines were functionally validated by assessing PS
157 externalization and PM integrity in live cells over time. As expected, knocking out CDC50A
158 resulted in increased basal levels of external PS relative to the parental HAP1 line throughout the
159 time course (**Figure 2A**). Conversely, HAP1 Δ XKR8 cells maintained the lowest levels of

160 external PS (**Figure 2A**). The activity of cellular flippases and scramblases is dynamically
161 regulated by stimuli such as apoptosis and calcium influx. To further validate the functional
162 phenotype of our KO lines, we infected cells with CHIKV (strain 181/c25), a known inducer of
163 apoptosis (56). Congruent with basal conditions, apoptotic HAP1 Δ CDC50A cells displayed the
164 highest levels of PS in the outer leaflet of the PM and HAP1 Δ XKR8 cells displayed the lowest
165 (**Figure 2B**). As hypothesized, CHIKV infection resulted in stronger induction of apoptosis
166 compared to basal levels, while cells lacking XKR8 remained low in outer leaflet PS under both
167 treatments (**Figure 2B**).

168 To validate our findings in an additional cell line, both XKR8 and CDC50A were KO in
169 VeroS cells (VeroS Δ XKR8 or VeroS Δ CDC50A). Consistent with the HAP1 background,
170 VeroS Δ CDC50A cells displayed the highest levels of outer leaflet PS in both untreated and
171 CHIKV infected cells (**Figure 2C, D**). In contrast, parental VeroS cells displayed
172 indistinguishable basal levels of externalized PS relative to VeroS Δ XKR8 cells (**Figure 2C**).
173 However, all VeroS lines lacked a strong signal of scrambling activity following CHIKV
174 infection (**Figure 2D**).

175 Next, we assessed the accessibility of PS on the viral envelope to verify that the lipid
176 orientation from the cellular PM, the site of CHIKV budding, is maintained. CHIKV particles
177 collected from each cell line were purified via ultracentrifugation. Normalized genome
178 equivalents were bound to beads for Annexin V immunofluorescent staining and a portion was
179 analyzed for CHIKV protein content. CHIKV glycoprotein (E) was detected at mostly similar
180 intensities from input virus via immunoblotting with α -CHIKV antibody, except that the input
181 from HAP1 Δ CDC50A appeared slightly lower (**Figure 2E**). Stain-free protein imaging
182 confirmed the level of capsid (C) protein was similar among the samples (**Figure 2E**). Congruent

183 with PS orientation on the cellular membrane, CHIKV particles produced from CDC50A KO
184 HAP1 cells bound a statistically higher number of annexin V molecules than HAP1 Δ XKR8
185 produced particles (**Figure 2F**). While external PS levels on CHIKV particles produced from
186 XKR8 scramblase KO HAP1 cells were significantly lower than WT, the trend between WT and
187 HAP1 Δ CDC50A did not achieve statistical significance, potentially due to a slightly lower
188 amount of HAP1 Δ CDC50A input virus (**Figure 2F**). In VeroS cells, similar intensities of
189 CHIKV E were detected via immunoblotting (**Figure 2G**) and C using the stain-free protein
190 staining (**Figure 2G**). Externalized PS detected on CHIKV particles from VeroS cells were
191 consistent with the PS orientation at the PM, where VeroS Δ CDC50A particles bound well to
192 annexin V, while particles produced in VeroS was indistinguishable from scramblase KO
193 VeroS Δ XKR8 (**Figure 2H**).

194 *Deleting CDC50A results in higher CHIKV titers in Vero cells*

195 Next, we evaluated if altered localization of cellular PS affected CHIKV viral titers in a
196 multi-cycle replication assay. If apoptotic mimicry enhances CHIKV infection, we expected viral
197 titers to be highest in our flippase KO lines as the PS-high virions produced from these cells
198 should bind PS receptors (PSRs) on naive host cells with increased efficiency in subsequent
199 rounds of infection and boost CHIKV entry. Conversely, the lack of exposed PS on virions
200 produced in scramblase KO cells should limit virion attachment to PSRs, resulting in fewer cells
201 infected and a net decrease in viral titers relative to parental lines.

202 Contrary to our expectations, CHIKV replication kinetics were similar among
203 HAP1 Δ CDC50A, HAP1, and HAP1 Δ XKR8 cells when titrated on HAP1 cells (**Figure 3A**).
204 HAP1 cells lack robust PSR expression (Horizon Discovery), and therefore we hypothesized
205 virion infectivity may appear equivalent if attachment occurs through non-apoptotic mimicry

206 associated molecules. Next, we titrated the same viral supernatants on VeroS cells to compare
207 viral titers in cells that contain the PSRs TIM-1 and AXL (47). When titrated on VeroS cells,
208 HAP1 Δ CDC50A cells consistently produced higher viral titers than the other HAP1 cell lines
209 (**Figure 3B**). No difference in viral titers was observed between HAP1 and scramblase KO
210 HAP1 Δ XKR8 cells (**Figure 3A, B**) despite XKR8 KO cells having substantially lower external
211 PS on the PM throughout the course of CHIKV infection (**Figure 2B**).

212 Multi-cycle replication assays were also performed in the VeroS background.
213 Interestingly, viral titers from our flippase KO VeroS Δ CDC50A cells were initially lower than
214 titers from parental cells, yet surpassed WT levels late in the course of infection (**Figure 3C**). As
215 with the HAP1 background, we found CHIKV replication kinetics were unaffected in our
216 scramblase KO line (VeroS Δ XKR8) compared to parental cells (**Figure 3C**). Thus, these data
217 suggest that CHIKV can achieve higher viral titers in the absence of CDC50A when infectivity is
218 quantified on Vero cells, but not HAP1 cells. Further, the lack of accessible PS on the cell
219 surface or the viral particle did not inhibit CHIKV infection relative to wild-type.

220 *CDC50A KO cells achieve higher viral titers without an increase in entry or cellular spread*

221 Differences in cell permissivity or susceptibility could result in more virions produced
222 per infected cell. This could explain the higher viral titers achieved in a multi-step replication
223 curve from CDC50A KO cells as opposed to increased particle infectivity mediated by improved
224 PS-PSR interactions. To assess for differences in permissivity or susceptibility, we determined
225 the number of particles produced from each cell line by quantifying the number of viral genomes
226 in the cellular supernatant at peak infection (36 hpi) during the multi-cycle replication curve
227 shown in **Figure 3**. Genome equivalents did not significantly vary between HAP1 Δ CDC50A,
228 HAP1, or HAP1 Δ XKR8 cells (**Figure 4A**). Consistent with the trends observed in the multi-step

229 growth curve (**Figure 3C**), genomes equivalents at 36 hpi were similar from VeroS and
230 VeroS Δ XKR8 cells compared to a statistically significant reduction in genomes equivalents from
231 VeroS Δ CDC50A cells (**Figure 4B**).

232 We next monitored the number of infected cells over time to discern if CHIKV was
233 spreading through CDC50A KO cells faster than parental or scramblase KO cell lines, which we
234 would hypothesize if PS-PSR interactions contribute to CHIKV infectivity. Contrary to our
235 expectations, all HAP1 cell lines were infected at similar rates across several rounds of CHIKV
236 infection (**Figure 4C**). While CHIKV spread through VeroS and VeroS Δ XKR8 cells at similar
237 rates, we observed a delay in the kinetics of CHIKV⁺ VeroS Δ CDC50A cells (**Figure 4D**).
238 However, once approximately 10% of the VeroS Δ CDC50A population was infected, CHIKV
239 spread at a rate similar to that of VeroS and VeroS Δ XKR8 cells (**Figure 4D**). Altering PS
240 orientation at the cellular PM did not alter CHIKV replication kinetics except in
241 VeroS Δ CDC50A cells, where viral spread was delayed. Thus, differences in cell permissibility
242 or susceptibility do not explain the overall increased viral titers observed in CDC50A KO cells
243 when titrated on a cell line that contains PSRs.

244 *CHIKV entry in Vero cells predominately utilizes PS receptors*

245 We hypothesized that virions with increased levels of PS on their outer leaflet (e.g. virus
246 produced in CDC50A KO cells) are more infectious due to a higher propensity to bind to cellular
247 surface PSRs. However, virus produced in cells high in outer leaflet PS have delayed viral spread
248 in VeroS Δ CDC50A cells and initially lower titers during in a multi-cycle replication curve when
249 quantified on VeroS cells (**Figure 3C**). We sought to examine why CHIKV infection was
250 delayed in VeroS Δ CDC50A cells, but not HAP1 Δ CDC50A cells.

251 First, we performed a high MOI entry experiment and monitored reporter gene
252 expression 12 hours following CHIKV infection in our CDC50A KO, XKR8 KO, and parental
253 cell lines. To ensure we captured a single round of replication, cells were treated with
254 ammonium chloride (NH₄Cl) either with viral inoculum or 2 hours after infection to prevent
255 endosomal acidification and synchronize infection. As expected, CHIKV infection was blocked
256 when NH₄Cl was added directly with the inoculum (**Figure 5A, B**). We found that the altered
257 cellular PS levels on our flippase and scramblase KO HAP1 lines did not affect the first round of
258 CHIKV viral entry (**Figure 5A**). In contrast, we observed a 94% reduction in CHIKV infected
259 flippase KO Vero Δ CDC50A cells relative to parental cells in the first round of infection and no
260 reduction in CHIKV⁺ Vero Δ XKR8 cells (**Figure 5B**). This strong entry inhibition corresponds
261 with the low CHIKV titers observed in Vero Δ CDC50A cells early in the multi-step replication
262 curve (**Figure 3C**) and initial delay in viral spread (**Figure 4D**).

263 Next, we investigated the mechanism behind the observed CHIKV entry inhibition in the
264 flippase KO Vero Δ CDC50A cells. Both the HAP1 and VeroS cell lines lacking CDC50A
265 contain high levels of PS in their outer leaflets (**Figure 2 A-D**). We hypothesized PS may
266 interact with PSR on neighboring cells causing PSR down regulation, inducing a lower steady-
267 state level of PSRs at the plasma membrane. The decreased levels of PSRs on CDC50A KO cells
268 could result in decreased virus entry mediated by viral apoptotic mimicry.

269 To determine if the CHIKV entry defect in Vero Δ CDC50A cells was associated with a
270 decrease of surface PSRs or an off-target effect of CDC50A deletion, virus entry was assessed in
271 a previously characterized AXL/TIM-1 double knockout Vero cell line (Vero Δ PSR) (47) and its
272 parental line (Vero). The absence of TIM-1 and AXL on the cellular surface of Vero Δ PSR cells
273 recapitulated the entry defect observed in Vero Δ CDC50A cells (**Figure 5B, C**). In addition,

274 adenovirus infection (non-enveloped, clathrin-mediated entry mechanism) did not result in an
275 entry defect into either Vero Δ CDC50A or Vero Δ PSR cells (**Figure 5D**). Lastly, the spread of
276 CHIKV through Vero Δ PSR cells was delayed relative to the parental Vero line (**Figure 5E**);
277 reflective of the viral spread kinetics observed among Vero Δ CDC50A cells (**Figure 4D**).
278 Collectively, these data suggest that CHIKV entry defect into Vero Δ CDC50A cells is related to
279 PSRs interactions and not a global viral entry defect.

280 To investigate if PSRs surface down-regulation was occurring in CDC50A KO cells, the
281 level of PSRs present on the cell surface was compared. According to Horizon Discovery mRNA
282 expression data, HAP1 cells produce the transcripts for the PSR TYRO3, but not other major
283 TIM or TAM family members. Proteins present at the cell surface of HAP1 cells were labeled
284 with biotin, purified, and TYRO3 was detected by immunoblot. Surface TYRO3 levels (SB)
285 were weaker from HAP1 Δ CDC50A relative to either parental HAP1 or HAP1 Δ XKR8 cells,
286 while total cell lysates (TL) for both β -Actin and TYRO3 was comparable across the three cell
287 lines (**Figure 5F**).

288 VeroS and Vero cells produce both TIM-1 and AXL (47), but not TYRO3 or Mer (57).
289 Immunofluorescence staining indicates that Vero Δ CDC50A cells display lower levels of both
290 AXL (**Figure 5G**) and TIM-1 (**Figure 5H**) compared to VeroS and Vero Δ XKR8 cells. Further,
291 Vero Δ PSR cells were confirmed to lack the surface presentation of both AXL (**Figure 5I**) and
292 TIM-1 (**Figure 5J**).

293 These data support that PSR surface downregulation is associated with the CHIKV entry
294 defect in flippase KO Vero Δ CDC50A cells. Interestingly, while PSR downregulation also
295 occurs in HAP1 Δ CDC50A cells, CHIKV entry remains unaffected. Thus, these data also suggest

296 that CHIKV entry into Vero cells is dependent on PS-PSR interactions, while entry into HAP1
297 cells is facilitated via alternative binding partners and is independent of PS-PSR interactions.

298 ***CHIKV infection is enhanced through viral apoptotic mimicry in a cell-type dependent***
299 ***manner in both mammalian and mosquito cells***

300 We infected a panel of commonly used mammalian and insect cell lines with CHIKV
301 virions containing discrete levels of envelope outer leaflet PS to determine the relevance of PS-
302 mediated cellular attachment amidst alternative attachment factors and receptors. Genome
303 equivalents were calculated for each viral inoculum and compared to the tissue culture infectious
304 dose 50 value (TCID₅₀) to calculate the particle to TCID₅₀ ratio as a metric of particle infectivity
305 on each cell type. We observed a correlation between the levels of PS on the particle and particle
306 infectivity when infecting Vero and VeroS cells (**Figure 6A, B**). Particles produced in HAP1,
307 flippase and scramblase KO cells displayed three levels of PS (**Figure 2F**) and three levels of
308 infectivity into Vero and VeroS cells (**Figure 6A, B**). Whereas virus made in VeroS, flippase and
309 scramblase KO cells only displayed two levels of PS on the virus (**Figure 2H**) and displayed two
310 levels of infectivity (**Figure 6A, B**). Infectivity did not correlate with particle PS when particles
311 were added to either HAP1, Vero Δ PSR, or NIH3T3 cells (**Figure 6A, B**). Our data suggest
312 CHIKV entry into Vero cells lines is altered by particle PS levels, while the infectivity of the
313 other tested mammalian cell lines is unaffected.

314 Based on the known CHIKV attachment factors present on HAP1 and VeroS cells, we
315 performed competitive inhibition assays to confirm the relevance of glycosaminoglycans and
316 phosphatidylserine receptors in facilitating CHIKV infection. As expected, luciferase signal
317 produced by CHIKV-*Nluc* infection decreased with the addition of increasing concentrations of
318 α -CHIKV antibody in a dose-dependent manner in HAP1 (**Figure 6C**) and Vero (**Figure 6D**)

319 cells. The addition of high concentrations of soluble heparan sulfate competed for CHIKV
320 infection in HAP1 cells (**Figure 6E**) but not Vero cells (**Figure 6F**). CHIKV infection in HAP1
321 cells was unaffected by the addition of PS containing liposomes (**Figure 6G**). Conversely, Vero
322 cells exhibited dose-dependent inhibition, where a ~90% reduction in infection was achieved
323 with 100 μ M liposomes (**Figure 6H**). These data support the cell-type dependence of CHIKV
324 entry factors, including viral apoptotic mimicry in specific mammalian cells.

325 The attachment factors promoting CHIKV entry into insect cells remain undefined.
326 Relative to mammalian cells, mosquito cells contain high levels of phosphatidylethanolamine
327 (PE) (58-60), which is another negatively charged phospholipid implicated in binding to PSRs
328 and viral apoptotic mimicry (48). Viral particles produced in the HAP1 cell lines did not alter
329 infectivity in C6/36 cells (**Figure 7A**), but HAP1 Δ CDC50A derived particles, high in outer
330 leaflet PS, increased particle infectivity in Aag2 cells (**Figure 7B**). In contrast, virus produced
331 from flippase activity KO VeroS cells enhanced CHIKV infectivity in both mosquito C6/36
332 (**Figure 7C**) and Aag2 (**Figure 7D**) cells.

333 CHIKV infection in C6/36 cells was inhibited with neutralizing α -CHIKV antibody
334 (**Figure 7E**) as expected, but unaffected by the addition of either heparan sulfate (**Figure 7F**) or
335 liposomes (**Figure 7G**). CHIKV infection in Aag2 cells was also blocked by α -CHIKV antibody
336 (**Figure 7H**) and, in contrast to C6/36 cells, infection was enhanced with heparan sulfate addition
337 (**Figure 7I**). We observed a reduction in CHIKV infection in Aag2 cells treated with our highest
338 concentration (100 μ M) of liposomes (**Figure 7J**), congruent with the enhanced infectivity in
339 Aag2 cells with particles produced in flippase KO cells (**Figure 7B, D**). These data support that
340 viral apoptotic mimicry can also enhance CHIKV infection in mosquito cells, but in a cell-type
341 dependent manner.

342

343 **Discussion**

344 In this study, we demonstrate that CHIKV entry into mammalian Vero cells and mosquito
345 Aag2 cells is enhanced through viral apoptotic mimicry, a process that involves PS on the virion
346 envelope binding to PSRs on the cellular surface. However, CHIKV infection in mammalian
347 HAP1 and NIH3T3 cells or mosquito C6/36 cells was not affected by virion-associated PS
348 levels, indicating that viral apoptotic mimicry for CHIKV is cell-type dependent (**Figure 8**).

349 The efficiency of CHIKV entry depends on which attachment factors are present. HAP1
350 cells endogenously produce GAGs (26) and the PSR TYRO3 (**Figure 5**). Our data supports that
351 CHIKV attachment to HAP1 cells occurs primarily through GAGs, as previously shown (26),
352 and is not PS-dependent. In contrast to HAP1 cells, Vero cells naturally produce the PSRs TIM-1
353 and AXL (47) and virion-associated PS enhances CHIKV infection in these cells. Further, PS
354 dependence was not observed to enhance CHIKV entry in mouse fibroblast NIH3T3 cells, which
355 display the nonessential proteinaceous receptor MXRA8 (22). The identity of CHIKV
356 attachment factors in the mosquito vector remains unresolved. Neither GAGs nor PS appear
357 involved in CHIKV infection in mosquito C6/36 cells. However, virions containing high
358 amounts of accessible PS produced from CDC50A KO cells were more infectious on Aag2 cells
359 and PS-containing liposomes inhibited CHIKV infection by 38%.

360 We verified that CHIKV acquires a particle envelope with a lipid bilayer composition
361 reflective of the cellular membrane from which it buds. Virions budding late in infection are
362 enriched in external PS as infected cells become apoptotic. These late produced PS-rich virions
363 can demonstrate improved infectivity through binding to nearby susceptible cells via PSRs.

364 Thus, apoptotic induction during CHIKV infection has pro-viral effects through improved
365 attachment efficiency. Viral apoptotic mimicry likely contributes to the broad host and cellular
366 tropism of CHIKV, but the relevance of this attachment mechanism in viral establishment,
367 dissemination, and transmission between humans and mosquitoes has yet to be determined *in*
368 *vivo*.

369 Prior characterization of the regulation of phospholipid distribution within the plasma
370 membrane (PM) lipid bilayer enabled us to alter natural phospholipid dynamics through the
371 deletion of key cellular proteins. These data confirm that knocking out flippase activity results in
372 the accumulation of PS on the outer leaflet of the PM. Further, low levels of PS are maintained
373 on the extracellular side of the lipid bilayer in scramblase KO HAP1 Δ XKR8 cells regardless of
374 whether the cell is healthy or apoptotic. Similar amounts of external PS between the parental
375 VeroS cells and our VeroS Δ XKR8 scramblase KO line even after CHIKV infection suggest that
376 VeroS cells contain low scramblase activity. A similar study examining Ebola particle infectivity
377 found that XKR8 was primarily distributed in Vero cell cytoplasmic membranes rather than the
378 PM, which may explain reduced PS scrambling on Vero cell surfaces (61).

379 Considering the prominent role of the PM in CHIKV replication, we investigated whether
380 viral kinetics, as opposed to particle infectivity, was altered in our flippase and scramblase KO
381 cell lines. CHIKV spread through the HAP1 cell lines at similar rates and produced similar levels
382 of viral progeny as evidenced by comparable levels of infectious particles when titrated on HAP1
383 cells. Preventing PS accumulation on the exterior of the host cell, as in the context of our
384 scramblase KO HAP1 Δ XKR8 line, did not appear to affect CHIKV replication kinetics. This
385 suggests that in the absence of PS attachment, CHIKV can efficiently use alternative
386 attachment factors to bind to HAP1 cells. Indeed, we found the glycosaminoglycan (GAG)

387 heparan sulfate, competitively inhibited CHIKV infection in HAP1 cells, supporting previous
388 findings (26). Interestingly, the boost in CHIKV infection with exogenous ectopic MXRA8 on
389 HAP1 cells suggests that even in the presence of native GAGs, the addition of a proteinaceous
390 receptor aids viral attachment efficiency, while TIM-1 addition did not (**Figure 1C**).

391 In contrast, CHIKV propagated through CDC50A KO cells produced particles that were
392 more infectious than those derived from WT or Δ XKR8 cells when titrated on VeroS cells.
393 Particles produced in Δ CDC50A cells contain higher levels of PS, suggesting CHIKV entry into
394 Vero cells can be promoted through apoptotic mimicry. Moreover, Vero cells lacking PSRs are
395 less susceptible to CHIKV infection, suggesting that in the absence of PSRs on Vero cells the
396 molecular components facilitating virion attachment and entry are inefficient. Interestingly, the
397 presentation of MXRA8 or additional TIM-1 on VeroS cells did not enhance CHIKV infection,
398 suggesting that the endogenous PSRs efficiently mediate CHIKV entry (**Figure 1D**). These data
399 further support the importance of affinity between virus-cell interactions in CHIKV entry.

400 NIH3T3 cells were the only cells examined which endogenously present MXRA8 on the
401 cellular surface (22). CHIKV infection in NIH3T3 cells was unaffected by viral envelope PS
402 levels (**Figure 6A, B**). MXRA8 is a nonessential proteinaceous receptor of CHIKV (22, 34, 62)
403 that binds to the E2 glycoprotein (63, 64), whereas TIM-1 binds PS lipids (48) on the virion
404 envelope. MXRA8 may promote stronger CHIKV cellular attachment compared to TIM-1 due to
405 either greater interaction accessibility based on virion structure or a stronger binding affinity.
406 While recent work has established that NIH3T3 cells have a low abundance of MXRA8 on the
407 cellular surface relative to human U2OS cells (26), the overall avidity between MXRA8 and
408 CHIKV-E is likely stronger than those between PSRs and virion-PS; negating any PS-dependent
409 attachment enhancement in NIH3T3 cells.

410 It is well documented that the attenuated CHIKV strain used in this study (181/c25)
411 displays increased GAG dependence compared to circulating pathogenic strains based on
412 interactions with residue 82 on E2 (25, 26, 65-67). The degree of GAG dependence appears to be
413 strain specific (26). Given that we observed viral apoptotic mimicry in Vero cells using a
414 CHIKV strain with strong GAG affinity, suggests that endemic strains may either (i) be more
415 reliant on alternative attachment factors such as PSRs and/or (ii) be less infectious in the same
416 context. A recent study found increased CHIKV infectivity with East-Central-South-African
417 (ECSA) strain LR2006-OPY1 and West African (WA) strain 37997 relative to Asian strain
418 181/c25 in 293T cells stably expressing TIM-1 or a TIM-1 variant lacking the cytoplasmic
419 domain (32).

420 In humans, CHIKV infection is initiated by virion deposition into the skin dermis during
421 the bite of an infectious female mosquito. Fibroblasts, keratinocytes, and resident macrophages
422 support initial CHIKV infection (22, 68). While fibroblasts are permissive for CHIKV, the
423 infection appears to be predominately MXRA8-dependent (22). Keratinocytes present in the
424 basal layer of the skin epidermis express both TIM-1 and AXL (50, 69) and are susceptible to
425 CHIKV infection (22). Interestingly, an immortalized keratinocyte cell line (HaCat) was shown
426 to be refractory to CHIKV infection due to an induction of interferon (68). However, a more
427 recent study demonstrated that HaCat cells produced low levels of AXL along with undetectable
428 levels of TIM-1, and that the addition of TIM-1 increased CHIKV susceptibility and permissivity
429 (32). Thus, keratinocytes may have a larger role in CHIKV infection establishment *in vivo* than
430 previously thought. Macrophages also display PSRs, conferring phagocytic properties of
431 apoptotic body clearance (70-72). PS-rich virions from either infected fibroblasts, keratinocytes,
432 or mosquito inoculation may serve as an ideal target to attach to PSRs on resident macrophages.

433 While macrophage infection via apoptotic mimicry could facilitate CHIKV dissemination *in*
434 *vivo*, macrophages often are poor producers of CHIKV virus *in vitro* (73).

435 Current evidence suggests that the long-term arthralgia associated with CHIKV infection
436 is due to immune-mediated tissue pathology (74, 75). While the cellular surface abundance of
437 MXRA8 overlaps with tissue types of pathogenic relevance (22, 34, 64, 74) and MXRA8
438 deficient mice have reduced joint pathology (34), apoptotic mimicry may promote initial
439 infection or dissemination as CHIKV infection *in vivo* still proceeds in MXRA8-deficient mice
440 (34). Future research should aim to understand the role of apoptotic mimicry in the context of
441 infection establishment and dissemination using *in vivo* model systems.

442 The transmission of CHIKV to a mosquito vector can occur when a susceptible mosquito
443 ingests blood from a viremic mammalian host. Key differences exist between mammalian-made
444 and mosquito-made virions that affect infectivity (76-82). For example, differences in protein
445 post-translation modifications between mammalian and invertebrate cells contribute to
446 differences in virion infectivity (N-glycosylation (80, 83)). In addition, the plasma membrane of
447 insect cells has a distinct lipid profile from that of mammalian cells (60, 84). While we did not
448 see strong support for viral apoptotic mimicry influencing CHIKV infection in mosquito C6/36
449 cells, CHIKV demonstrated PS-dependent enhancement in mosquito Aag2 cells. In Aag2 cells,
450 we observed that elevated externalized PS levels increased CHIKV particle infectivity and PS-
451 liposomes inhibited CHIKV infection. Given the clear role of cell type in dictating PS
452 dependence, it may not be appropriate to conclude the role of viral apoptotic mimicry in
453 mosquitoes from either C6/36 cells or Aag2 cells, which are not representative of the cell types
454 implicated in natural infection. Cell factors that facilitate CHIKV entry into mosquito cells
455 remain elusive, however, mosquitoes do not produce homologs to MXRA8 (34), drosophila

456 encode PSR orthologs, and apoptotic cell clearance via phosphatidylserine exposure is conserved
457 (85).

458 The examination of CHIKV entry efficiency throughout infection *in vivo* is needed to
459 delineate the relevance of attachment via PSRs among other surface molecules including GAGs
460 and MXRA8 in influencing infection establishment, dissemination, and cross-species
461 transmission. Future studies should aim to robustly characterize the role of each CHIKV
462 attachment factor, including viral apoptotic mimicry, in systems that more closely resemble
463 natural infection.

464

465 **Materials & Methods**

466 *Cell lines*

467 Human near-haploid cells (HAP1) derived from the male chronic myelogenous leukemia cell
468 line KBM-7, HAP1 flippase KO line (HAP1 Δ CDC50A, HZGHC005423c007), and HAP1
469 scramblase KO line (HAP1 Δ XKR8, HZGHC005916c007) were purchased from Horizon
470 Discovery (United Kingdom). HAP1 and HAP1 KO lines were cultured in Iscove's modified
471 Dulbecco's medium (IMDM) supplemented with 8% (v/v) fetal bovine serum (FBS). All vervet
472 monkey cells (VeroS, VeroS Δ CDC50A, VeroS Δ XKR8, Vero, and Vero Δ PSR,) were maintained
473 with DMEM supplemented with 5% (v/v) FBS. The Vero and Vero Δ PSR cells were a kind gift
474 from Dr. Wendy Maury at the University of Iowa (47). Mouse embryo fibroblasts cells
475 (NIH3T3) were purchased from ATCC (CRL-1658) and maintained with DMEM supplemented
476 with 10% (v/v) FBS. All mammalian cells were kept in a humidified chamber held at 37°C and
477 with a 5% CO₂ content. Mosquito *Aedes albopictus* C6/36 (ATCC, CRL-1660) were maintained
478 with Leibovitz's L-15 medium supplemented with 10% (v/v) FBS in a humidified chamber held

479 at 28°C. *Aedes aegypti* Aag2 (ATCC, CCL-125) larval homogenate cells were maintained in
480 SFX insect medium with 2% (v/v) FBS in a humidified chamber at 28°C.

481 ***CRISPR-Cas9 mediated generation of VeroS KO cell lines***

482 Three guide RNAs targeting each *Chlorocebus sabaues* gene, XKR8
483 (GGCACTGCTCGACTACCACC, TGATCTACTTCCTGTGGAAC,
484 CAGCTATGTGGCCCTGCACT) and CDC50A (TACGGCTGGCACGGTGCTAC,
485 TCGTCGTTACGTGAAATCTC, GTGAACTGGCTTAAACCAGT), were inserted
486 into pSpCas9(BB)-2A-GFP (pX458), which was a gift from Feng Zhang (Addgene plasmid
487 #48138) (86) and verified using Sanger sequencing. VeroS cells were transfected with equivalent
488 amounts of pSpCas9(BB)-2A-GFP bearing each of the three guide RNAs using GeneJuice
489 (Sigma-Aldrich, cat. 70967). Three days post-transfection, VeroS cells were counted and
490 distributed at a density of 0.5 cells per well into 96-well plates. Cells were monitored for 3 weeks
491 to maintain single colony clones, and non-clonal wells were discarded. Wells corresponding to
492 single clones were expanded to 24-well plates and assessed for CRISPR knockout. CRISPR
493 XKR8 and CDC50A KOs were validated by extracting total DNA and PCR amplifying the guide
494 RNA targeted regions. PCR amplicons spanning *xkr8* CRISPR regions were gel purified and
495 submitted for Sanger sequencing to verify *xkr8* modification, which showed a 136 bp deletion in
496 exon 2. We could not amplify *cdc50a* CRISPR regions in exons 1 and 3 but could amplify the
497 CRISPR region targeting exon 5, indicating the presence of a large deletion spanning multiple
498 exons in CDC50A. CRISPR CDC50A KO was also validated using a functional screen for
499 externalized PS. Cells were washed in PBS and the media was changed to Annexin V binding
500 buffer (1mM HEPES pH 7.4, 14 mM NaCl, 0.25mM CaCl₂) with Annexin V-PE conjugate at
501 1:50 (v/v) and incubated at room temperature for 15 mins. Cells were washed with Annexin V

502 binding buffer and visually analyzed under a fluorescence microscope. Cells with high PS
503 staining compared with parental cells were expanded for future experiments. Parental cells were
504 treated with 1 mM MG132 for 2 hrs were used as a positive signal control.

505 ***DNA transfections***

506 Transfection efficiency and cytotoxicity varied with each cell line and gene KO. We paired
507 different transfection reagents with different cell lines to optimize transfection efficiency and
508 reduce cytotoxicity. All HAP1 cells were transfected with JetOptimus (PolyPlus, cat. 117-07),
509 VeroS, VeroS Δ XKR8 and 293T cells with GeneJuice (Sigma-Aldrich, cat. 70967), and CDC50A
510 KO lines with Viafect (Promega, cat. E4981) according to manufacturer recommendations.
511 Expression vectors encoding a GFP-fused transmembrane hTIM-1 (a gift from Wendy Maury at
512 the University of Iowa), pCS6-L-SIGN (Transomic; cat. BC038851), pTiger-MXRA8, or
513 pCMV-GFP were used to assess CHIKV virion surface binding kinetics.

514 ***Viruses***

515 Chikungunya virus (CHIKV) strain 181 clone 25 (181/c25) was used to conduct experiments in a
516 BSL2 laboratory environment. Full-length DNA CHIKV clones containing reporter genes (*gfp*,
517 *mKate*, or *Nluc*) were linearized and *in vitro* transcribed (Ambion, cat. AM1344) adhering to the
518 manufacturer's protocol. Infectious CHIKV virions expressing reporter genes were recovered
519 after direct RNA transfection (1 μ g) into VeroS cells with Lipofectamine 3000 (ThermoFisher,
520 cat. L3000001). Unless otherwise stated, viral stocks were propagated in VeroS cells and passage
521 3 viral stocks were used for all experiments. The amount of infectious virus was determined by
522 calculating the 50% tissue culture infective dose (TCID₅₀) units per mL through end-point
523 dilution using the Spearman-Kärber method (87). Replication deficient adenovirus

524 (Ad5CMVeGFP) was purchased from UI Viral Vector Core Web at a predetermined high titer of
525 5×10^{10} PFU/mL.

526 ***Real-time quantification PCR (RT-qPCR) of genome equivalents***

527 CHIKV genome equivalents/mL were calculated via RT-qPCR. Viral RNA was extracted from
528 infected cell supernatant (Zymo, cat. 11-355), eluted in nuclease-free water, and converted to
529 cDNA with random hexamers (ThermoFisher, cat. 4388950) following kit protocols. RT-qPCR
530 reactions were set up with cDNA, TaqMan Gene Master Mix (Applied Biosystems, cat.
531 4369016), primers, and TaqMan probe (5'-
532 6FAMACTTGCTTTGATCGCCTTGGTGAGAMGBNFQ-3') as previously described (88) with
533 each sample run in duplicate. A plasmid-based standard curve of a full-length CHIKV clone was
534 used to enumerate the total number of genome equivalents per mL of the original sample. A no
535 template control (NTC) and no amplification control (NAC) were included in each run on a
536 StepOne platform (Applied Biosystems, cat. 4376357). The amplification profile included 1
537 cycle of 2 mins at 50°C, 10 mins at 95°C, followed by 40 cycles of 15 secs at 95°C and 1min at
538 60°C.

539 ***293T immunofluorescence staining***

540 293T cells were plated at 2.0×10^5 cells per well in 12-well plates 48 hrs before
541 immunofluorescence staining. Cells were transfected with plasmids encoding MXRA8, hTIM-1-
542 GFP, or L-SIGN along with a plasmid encoding GFP 24 hrs before immunofluorescence
543 staining. Transfected cells were rapidly cooled and stained in blocking solution (dPBS with 2%
544 (v/v) bovine serum albumin (BSA)) containing anti-MXRA8 (1:100, W040-3, MBL
545 International), anti-hTIM1(1:100, AF1750, R&D Systems), or anti-CLEC4M (L-SIGN/CD299)
546 2G1 antibody (1:100, MA5-21012, Thermo) at 4°C with gentle shaking for 1 hr. Cells were

547 washed with PBS before lifting the cells with a scraper. Cells were pelleted (500xg for 5 mins),
548 resuspended, and washed in PBS two additional times before adding secondary anti-goat Cy5
549 (1:2500, 072-02-13-06, KPL) or anti-mouse Alexa Fluor 647 (1:2500, A32728, Invitrogen) and
550 incubated at 4°C in the dark for 30 mins. Cells were washed with PBS three times and then
551 analyzed via flow cytometry. Cell populations were gated using forward scatter/side scatter. The
552 mean fluorescence intensity (MFI) of a minimum of 10000 GFP positive cells were quantified
553 per experimental condition and performed three independent times. Secondary only and GFP
554 only transfected cells were stained with primary and secondary antibodies and used as controls
555 for all conditions. All cells were analyzed using a NovoCyte Quanteon (Aligent) flow cytometer.

556 ***Quantification of cellular outer leaflet phosphatidylserine (PS)***

557 Cellular surface levels of PS were assessed using Promega's RealTime-Glo Annexin V
558 Apoptosis and Necrosis Assay (Promega, cat. JA1012) according to manufacturer specifications.
559 HAP1 or VeroS cell lines were plated in media supplemented with 0.1 M HEPES at 3.0×10^4 or
560 10^4 cells per well, respectively, in a 96-well black-walled, clear bottom plate 1 day prior to
561 treatment. Cells were infected with CHIKV-*mKate* (MOI of 1.0) or mock infected. Kit
562 components 1-4 were added to cells 1 hr following infection and the plate was moved into a pre-
563 warmed GloMax Explorer. Kit components 1-4 were used when assaying HAP1 cells at 0.5x
564 concentration as cytotoxicity was observed at 1x manufacturer recommendations. Automated
565 luminescence (Annexin V) and fluorescence (membrane integrity) measurements were collected
566 every 30 mins in a GloMax Explorer (Promega) held at 37°C.

567 ***Quantification of viral outer leaflet phosphatidylserine (PS)***

568 *Virus Production:* T75 flasks were seeded with wild type, Δ XKR8, and Δ CDC50A HAP1 and
569 VeroS cells with 7.2×10^6 cells or 3.6×10^6 cells, respectively. After 24 hrs, wild-type and

570 Δ XKR8 cells were infected with CHIKV using MOI =0.001 and Δ CDC50A cells were infected
571 using MOI=0.01. After 12 hrs at 37°C, inoculum was removed, cells were treated with citric acid
572 buffer (40 mM citric acid, 10 mM KCl, 135 mM NaCl [pH 3.0]) for 1 min, rinsed, and FBS-free
573 media was added. After incubating for an additional 36 hrs, the supernatant was collected,
574 cleared twice using centrifugation (6,000xg) and overlaid on a 20% sucrose cushion. Overlaid
575 supernatants were then subjected to ultracentrifugation at (234,116xg) for 2 hrs at 4°C. Pellets
576 were resuspended in 100 μ L PBS.

577 *Input normalization:* Prior to staining, purified CHIKV samples were normalized using RT-
578 qPCR: To detect CHIKV capsid (C) levels, normalized samples were denatured using SDS-urea
579 buffer (200 mM Tris [pH 6.8], 8 M urea, 5% SDS, 0.1 mM EDTA, 0.03% bromophenol blue),
580 run on Mini-PROTEAN TGX Stain-Free Precast Gels (Bio-Rad), and imaged with a ChemiDoc
581 XRS digital imaging system (Bio-Rad). Gels were then subjected to immunoblot analysis for
582 CHIKV E using an anti-E antibody (1:1000, R&D Systems, MAB97792SP).

583 *Particle surface PS staining:* Equivalent numbers of CHIKV particles were conjugated to 4- μ m
584 aldehyde/sulfate latex beads (Thermo Fisher Scientific) overnight at 4°C with gentle shaking.
585 Due to differences in viral yields between cell types, beads were bound with approximately 10^6
586 genome equivalents from HAP1 cell lines and 10^9 genome equivalents from VeroS cell lines.
587 Beads were blocked with a final concentration of 1% (v/v) bovine serum albumin (BSA) in PBS
588 for 2 hrs while rotating at room temperature. Beads were washed 3 times with 1% (v/v) BSA in
589 PBS and then incubated with 100 μ l of AnV binding buffer containing AnV-PE conjugate for 30
590 mins on ice. Beads were diluted 1:4 in AnV binding buffer and analyzed using the NovoCyte
591 Quanteon flow cytometer (Aligent). Bead only samples were included as a mock control.

592 *Multi-step CHIKV replication kinetics*

593 A low MOI (0.01) was used to assess replication kinetics over multiple replication cycles. Cells
594 were seeded at a density of 3×10^5 cells/mL for HAP1 lines and 2.5×10^5 cells/mL for VeroS lines
595 and inoculated with virus in FBS-free media for 1 hr at 37°C before removing viral inoculum
596 and replacing with complete media. At each time point, the supernatant was collected, and fresh
597 media was replaced. Supernatants were frozen at -80°C until all time-points were collected.
598 Virus was titrated on the indicated cell line and the number of infectious particles per mL was
599 calculated by determining the 50% tissue culture infective dose (TCID₅₀) as described above.

600 *Cell-to-cell viral spread kinetics*

601 Cells were plated at either 7.5×10^4 cells per well in a 48-well plate (HAP1 lines) or 5×10^4 cells
602 per well in a 24-well plate (Vero lines) 1 day prior to infection. Assuming cells doubled
603 overnight, cells were inoculated with CHIKV-GFP virus (MOI of 0.1). After 1 hr (T = 0 hpi)
604 virus inoculum was removed and replaced with complete media. At the indicated time, cells were
605 lifted in trypsin, resuspended in PBS, and fixed in 1.5% (v/v) formaldehyde. GFP positive cells
606 were enumerated in a NovoCyte Quanteon (Aligent) flow cytometer. Cells were first gated based
607 on forward/side scatter, and cellular aggregates were removed by gating with forward scatter
608 area to height. Uninfected cells were used to set the GFP gate. 10000 live cells were collected
609 and the percent infection (% GFP+) was recorded and compared over time.

610 *Entry assays*

611 Viruses expressing *gfp* were used to determine if cellular attachment and internalization varied
612 across cell lines. 7.5×10^4 cells per well were plated in a 48-well format for HAP1 cell lines and
613 5×10^4 cells per well in a 24-well format for Vero cell lines 1 day prior to infection. A high MOI
614 was used to infect ~50% of the cell population in the initial round of infection. Virus inoculum
615 was added to cells for 1 hr at 37°C after which viral inoculum was removed and replaced with

616 complete medium, marking 0 hpi. CHIKV requires low pH in the endosome for membrane
617 fusion and genome release. To ensure we were measuring GFP production from only the first
618 round of infection for CHIKV, 30 mM ammonium chloride (NH₄Cl) was added 2 hpi or with
619 virus inoculum to demonstrate blocking potency. Cells were lifted at either 12 hpi (CHIKV) or
620 20 hpi (AdenoV), resuspended in PBS, and fixed with 4% formaldehyde. A NovoCyte Quanteon
621 (Aligent) flow cytometer was used to determine the percentage of GFP⁺ cells. Cell gating was
622 the same as described above for viral spread.

623 *Surface biotinylation*

624 Parental HAP1 and KO lines were seeded at 5x10⁵ cells per well in a 6-well plate and incubated
625 for 48 hrs. Cells were then washed with cold PBS and biotinylated with 0.5 mg/ml
626 sulfosuccinimidyl-2-(biotinamido) ethyl-1,3-dithiopropionate (ThermoFisher) while gently
627 shaking for 45 mins on ice. The reaction was quenched using Tris-HCl. Cells were lysed in M2
628 lysis buffer (50 mM Tris [pH 7.4], 150 mM NaCl, 1 mM EDTA, 1% Triton X-100) at 4°C and
629 clarified with centrifugation at 17,000Xg for 10 min. To purify surface exposed proteins, lysates
630 were incubated with streptavidin sepharose beads (GE Healthcare) overnight while rotating at
631 4°C. Following incubation, the streptavidin sepharose beads were washed in buffer 1 (100 mM
632 Tris, 500 mM lithium chloride, 0.1% Triton X-100) and then in buffer 2 (20 mM HEPES [pH
633 7.2], 2 mM EGTA, 10 mM magnesium chloride, 0.1% Triton X-100), incubated in urea buffer
634 (200 mM Tris [pH 6.8], 8 M urea, 5% sodium dodecyl sulfate [SDS], 0.1 mM EDTA, 0.03%
635 bromophenol blue, 1.5% dithiothreitol [DTT]) for 30 min at 56°C, and subjected to immunoblot
636 analysis using anti-βactin C4 (1:1000, Santa Cruz Biotechnology, sc-47778) and anti-Tyro-3
637 (1:1000, R&D Systems, MAB859100) antibodies. Immunoblots were probed with appropriate

638 secondary antibodies conjugated with HRP and imaged with a ChemiDoc XRS digital imaging
639 system (Bio-Rad).

640 *Vero immunofluorescence staining*

641 Vero cell lines were plated at 10^5 cells per well in a 24-well format 24 hrs before
642 immunofluorescence staining. Cells were rapidly cooled by placing cells on ice and replacing
643 media with ice cold PBS for 15 mins. PBS was removed and replaced with 200 μ L of blocking
644 solution (dPBS with 2% (v/v) BSA) containing α -TIM1(1:100, AF1750, R&D Systems) or α -
645 AXL antibody (1:100, AF154, R&D Systems) and incubated at 4°C and gently shook for 1 hr.
646 Cells were washed three times with PBS. Following the third wash, 200 μ L of blocking solution
647 containing α -goat Cy5 (1:2500, 072-02-13-06, KPL) and incubated at 4°C in the dark and gently
648 rocked for 30 mins. After three PBS washes, cells were scraped, homogenized, and analyzed via
649 flow cytometry. Cell populations were gated using forward scatter/side scatter. The mean
650 fluorescence intensity (MFI) of a minimum of 5,000 live cells was quantified per experimental
651 condition. Secondary only was used as a negative control in all conditions. All cells were
652 analyzed using a NovoCyte Quanteon (Aligent) flow cytometer.

653 *Particle infectivity*

654 We used the ratio of genome equivalents to infectious viral particles to assess particle infectivity.
655 This ratio represents the number of particles needed to start an infection. A smaller value
656 indicates a virus stock is more infectious, or each particle has a higher probability of starting an
657 infection. Particle number was determined by quantifying the number of genome equivalents in
658 the virus preparation using qRT-PCR described above. Infectivity was determined by TCID₅₀
659 units per mL. CHIKV readily forms plaques on VeroS cells, however, not all our cell lines

660 tolerated forming a confluent monolayer under an agar overlay and therefore TCID₅₀ units were
661 used when comparing various cell lines.

662 *Competition assays*

663 CHIKV-*Nluc* stocks were used to assess the ability of antibody, liposomes, or heparin sulfate to
664 block infections into the indicated cell lines. HAP1 cells were seeded at 5x10⁴ cells per well in a
665 96-well plate 1 day prior to infection. For each well in the competition assay approximately 150
666 CHIKV-*Nluc* virions were added. 24 hrs following infection, cells were lysed with NanoGlo
667 substrate and lysates were quantified in a GloMax Explorer (Promega) according to
668 manufacturer's instructions for all competitive inhibition assays.

669 *Antibody competition:* virus was incubated with the indicated concentrations of CHIKV
670 polyclonal antibody (IBT, cat. 04-008) or no antibody control at room temperature for 45 mins.
671 After incubation, the virus-CHIKV antibody mix was added to cells.

672 *Heparan competition:* the indicated concentration of heparan sulfate (Sigma-Aldrich, cat.
673 H7640-1MG), or control PBS was added to cells at 37°C for 10 mins prior to infection. After the
674 10 min pre-treatment, virus was added.

675 *Liposome competition:* the indicated concentration of liposomes (30% PS: 69% PE: 1% PC) (48)
676 or PBS was added to cells at 37°C for 10 mins prior to infection. After the 10 min pre-treatment,
677 virus was added.

678 *Statistical analysis*

679 Data were visualized and analyzed using GraphPad Prism software (v8.2.1, windows 64-bit). An
680 unpaired parametric Student T-test assuming equal variance was used to test for statistical
681 significance for data on a linear scale (e.g., percent infected). An unpaired parametric Student T-
682 test using a Welch's correction was used to test for statistical significance for normalized data

683 (e.g., relative infection, normalized MFI). Logarithmic data were natural log (ln) transformed
684 and then assessed with an unpaired parametric Student T-test assuming equal variance (e.g.,
685 genome equivalents, specific infectivity).

686 **Acknowledgements**

687 We would like to thank James Barber and the CVM flow cytometer core at the University of
688 Georgia for their technical assistance.

689 **Funding**

690 KM was partially supported by an NSF Graduate Research Fellowship Program. AJ was
691 supported by the NIH Post-baccalaureate Training in Infectious Disease Research (GM109435).
692 The research reported in this publication was supported by the National Institute of Allergy and
693 Infectious Diseases of the National Institutes of Health under Award Number R01AI139238
694 (MB) and R01AI139238-S1 (JMRB). The content is solely the responsibility of the authors and
695 does not necessarily represent the official views of the National Institutes of Health or National
696 Science Foundation. This material is based upon work supported by the National Science
697 Foundation Graduate Research Fellowship Program under Grant Nos. 1443117 (KM) and
698 1842396 (KM and JMRB). Any opinions, findings, and conclusions or recommendations
699 expressed in this material are those of the author(s) and do not necessarily reflect the views of
700 the National Science Foundation.

701

702 **Figure 1. Overexpression of TIM-1 enhances CHIKV infection in a cell-dependent manner.**

703 (A) 293T cells were assessed for the surface presentation of known CHIKV attachment factors
704 (TIM-1, MXRA8, or L-SIGN) via flow cytometry. 293T cells were transfected with either TIM-
705 1, MXRA9, L-SIGN, or GFP 24 hrs prior to the addition of primary antibodies specific against
706 hTIM-1, MXRA8, or L-SIGN. 24 hrs post transfection, 293T, HAP1, and VeroS cells were
707 inoculated with either (B-D) mKate-expressing CHIKV strain 181/c25, (E-G) recombinant
708 vesicular stomatitis virus containing the Lassa virus glycoprotein (rVSVΔG/LASV), or (H-J)
709 rVSV studded with the Ebola virus glycoprotein (rVSVΔG/EBOV) for 1 hr. 12 hrs post
710 infection, cells were assessed for CHIKV infection (mKate⁺) and transfection efficiency (GFP⁺)
711 via flow cytometry. Relative infection was calculated as the proportion of cells infected with
712 CHIKV (mKate⁺) among transfected cells (GFP⁺) normalized to infection levels in a GFP only
713 control well. At least three independent replicates were performed with each bar representing the
714 mean and error (\pm SEM) with an unpaired parametric Student's T-test with unequal variance
715 (Welch's correction) was used to determine statistical significance, where * ($p < 0.05$), ** ($p <$
716 0.01), *** ($p < 0.001$).

717 **Figure 2. Knocking out flippases and scramblases affects the amount of externalized**
718 **cellular PS.** HAP1 cell lines and VeroS cell lines were monitored for Annexin V binding (RLU)
719 for 36 hrs with automated measurements taken every 30 mins using a GloMax Explorer
720 multimode microplate reader held at 37°C. Parental, scramblase XKR8 KO, and flippase subunit
721 CDC50A KO cells were either (A, C) untreated (Basal) or treated with (B, D) viral infection
722 (CHIKV strain 181/c25, MOI 1.0). Three independent replicates were performed with the solid
723 line representing the mean and faded region indicating the error (\pm SEM). To quantify levels of
724 externalized PS on the CHIKV viral particle, CHIKV was propagated through both HAP1 and
725 VeroS cell lines. (E, G) Viral inputs were immunoblotted with an α -CHIKV antibody and
726 accessed for purity using a stain-free gel. (F, H) Annexin V conjugated to PE was used to stain
727 normalized amounts of virus-bound beads and quantified via FACs analysis. A bead only control
728 (mock) was used to establish a baseline signal. MFI values from three independent trials were
729 normalized to parental values (HAP1 or VeroS) with the mean and \pm SEM displayed. An
730 unpaired parametric T-test with Welch's correction was used test for statistical significance,
731 where * ($p < 0.05$), ** ($p < 0.01$), *** ($p < 0.001$).

732 **Figure 3. Multi-step CHIKV replication kinetics.** Multi-step replication kinetics of CHIKV
733 strain 181/c25 (MOI = 0.01) in parental, scramblase XKR8 KO, or flippase subunit CDC50A
734 KO cells. Cellular supernatants from HAP1 cell lines were titrated on either (A) HAP1 cells or
735 (B) VeroS cells. (C) Cellular supernatants from VeroS cell lines were titrated on VeroS cells.
736 Three independent replicates were performed with error bars representing \pm SEM.

737 **Figure 4. Increased CHIKV titers in CDC50A KO cells are not due to increased viral**
738 **production or cellular spread.** The number of genome copy equivalents per mL were
739 determined from the cellular supernatants collected at 36 hrs post infection (peak infection) from
740 the multi-step replication curve (MOI = 0.01) in **Figure 3** with real-time qPCR for each **(A)**
741 HAP1 cell line and **(B)** VeroS cell line. Genome copy equivalents per mL were natural log (ln)
742 transformed prior to performing an unpaired parametric student T-test relative to parental cells
743 (HAP1 or VeroS). CHIKV cellular spread kinetics were quantified by FACs analysis of the
744 percent of GFP⁺ cells over time after CHIKV-*gfp* infection (MOI = 0.1) in **(C)** HAP1 lines or **(D)**
745 VeroS lines. Three independent replicates were conducted with error bars representing \pm SEM.
746 Values of significance are shown as * ($p < 0.05$), ** ($p < 0.01$), *** ($p < 0.001$).

747 **Figure 5. CHIKV entry in Vero cells predominately utilizes PS receptors.** CHIKV-*gfp* (strain
748 181/c25) stock virus was used to infect either (A) HAP1 lines (MOI = 10), (B) VeroS lines (MOI
749 = 100) or (C) Vero lines (MOI = 100). 30mM ammonium chloride (NH₄Cl) was added with the
750 viral inoculum (0hr: hollow bars) or 2 hrs post inoculum removal (2hr: solid bars). At 12 hrs post
751 infection, the percent of cells infected (GFP⁺) was determined by FACs analysis. Three
752 independent replicates were conducted with error bars representing ±SEM. Unpaired parametric
753 student T-tests were performed relative to the parental cell line (HAP1, VeroS, or Vero). (D) A
754 viral inoculum was used to achieve ~60% of cells infected with AdenoV in parental VeroS and
755 Vero cells. Viral inoculum was removed and replaced with complete media 2 hrs post infection.
756 At 20 hrs post infection, the percent of infected cells (GFP⁺) was determined by FACs analysis
757 (E) CHIKV cellular spread kinetics were quantified by FACs analysis of the percent of GFP⁺
758 cells over time after CHIKV-*gfp* infection (MOI = 0.1) in Vero and VeroΔPSR cells. Three
759 independent replicates were conducted with error bars representing ±SEM. (F) HAP1,
760 HAP1ΔXKR8, and HAP1ΔCDC50A cells were immunoblotted for the PSR TYRO3 in both the
761 total cell lysate (TB) and surface (SB). β-Actin immunoblotting of the TL served as a protein
762 loading control. A representative image of two independent trials is displayed. The surface
763 presentation of the PSR (G) AXL or (H) TIM-1 on each VeroS cell line was assessed with
764 immunofluorescence. The mean fluorescence intensity (MFI) was normalized to the parental
765 value within each trial with the mean and ±SEM represented. An unpaired parametric student T-
766 test with a Welch's correction was performed with mean normalized MFI values relative to
767 parental cells. Surface levels of (I) AXL or (J) TIM-1 were assessed for Vero and VeroΔPSR
768 cells as described above. Values of significance are shown as * ($p < 0.05$), ** ($p < 0.01$), *** (p
769 < 0.001).

770 **Figure 6. CHIKV viral apoptotic mimicry is cell-type dependent in mammalian cells.** The
771 particle (genome copy equivalents) per mL to TCID₅₀ units per mL ratio for each sample was
772 used to assess the infectivity of particles produced from (A) HAP1 cell lines or (B) VeroS cell
773 lines on a panel of commonly used mammalian cell types (human HAP1, monkey Vero, and
774 mouse NIH3T3). CHIKV virions were collected from the producer cell at 24 hrs post CHIKV
775 infection (MOI of 1.0). Congruent with TCID₅₀ methods, equal volumes of collected virus were
776 added to each cell line in the panel without inoculum removal and scored based on CPE and
777 GFP⁺. At least three independent replicates were conducted with bars representing the mean and
778 error (\pm SEM). Infectivity values were natural log (ln) transformed prior to performing an
779 unpaired parametric student T-test relative to parental cells. (C-H) CHIKV-*Nluc* stocks were
780 used to assess the ability of (C, D) CHIKV antibody, (E, F) heparan sulfate, or (G, H) PS-
781 containing liposomes (30% PS: 69% PE: 1% PC), to block infections into either HAP1 or Vero
782 mammalian cells at the indicated concentrations. Twenty-four hours following infection the cells
783 were lysed with NanoGlo substrate and lysates were quantified with a GloMax Explorer. At least
784 three independent replicates were conducted with dots representing means and error bars
785 representing \pm SEM. Values of significance are shown as * ($p < 0.05$), ** ($p < 0.01$), *** ($p <$
786 0.001).

787 **Figure 7. CHIKV viral apoptotic mimicry is cell-type dependent in mosquito cells.** The
788 particle (genome copy equivalents) per mL to TCID₅₀ units per mL ratio for each sample was
789 used to assess the infectivity of particles produced from **(A, B)** HAP1 cell lines or **(C, D)** VeroS
790 cell lines on mosquito **(A, C)** C6/36 and **(B, D)** Aag2 cells. Congruent with TCID₅₀ methods,
791 equal volumes of collected virus were added to each cell line in the panel without inoculum
792 removal and scored based on CPE and GFP⁺. At least three independent replicates were
793 conducted with bars representing the mean and error (\pm SEM). Infectivity values were natural log
794 (ln) transformed prior to performing an unpaired parametric student T-test relative to parental
795 cells. **(E-J)** CHIKV-*Nluc* stocks were used to assess the ability of **(E, H)** CHIKV antibody, **(F, I)**
796 heparan sulfate, or **(G, J)** PS-containing liposomes (30% PS: 69% PE: 1% PC), to block
797 infections into either C6/36 or Aag2 mosquito cells at the indicated concentrations. Twenty-four
798 hours following infection the cells were lysed with NanoGlo substrate and lysates were
799 quantified with a GloMax Explorer. At least three independent replicates were conducted with
800 dots representing means and error bars representing \pm SEM. Values of significance are shown as
801 * ($p < 0.05$), ** ($p < 0.01$), *** ($p < 0.001$).

802 **Figure 8. CHIKV viral apoptotic mimicry is cell-type dependent.** A visual summary of the
803 current study and main findings. To study the role of viral apoptotic mimicry in CHIKV
804 infection we generated CHIKV virions with distinct levels of phosphatidylserine (PS) exposed
805 on the viral envelope. First, HAP1 and VeroS cells were genetically modified by creating either a
806 flippase subunit KO line (Δ CDC50A) or a scramblase KO line (Δ XKR8) to exploit natural
807 phospholipid translocation dynamics. Abolishing flippase activity (Δ CDC50A) resulted in cells
808 with constitutively high levels of externalized PS in the plasma membrane, whereas impairing
809 scramblase activity (Δ XKR8) resulted in low levels of PS. Next, CHIKV virus was passaged
810 once through each genetically modified cell line to produce viral particles with discrete levels of
811 PS in the outer leaflet of the virion envelope. These produced particles were placed on several
812 cell lines with unique combinations of identified CHIKV attachment factors to assess the role of
813 viral apoptotic mimicry during CHIKV infection in both mammalian (HAP1, Vero, and
814 NIH3T3) and mosquito (C6/36 and Aag2) cells. We found the role of viral apoptotic mimicry in
815 CHIKV infection to occur in a cell type dependent manner. Our data support that GAGs such as
816 heparan sulfate are a major contributor to infection in HAP1 cells, while the PSR TYRO3 is not.
817 CHIKV PS levels correlated with infectivity in Vero cells containing the PSRs TIM-1 and AXL,
818 providing a role of viral apoptotic mimicry in CHIKV entry. Further, we found CHIKV
819 infectivity on NIH3T3 cells to be unaffected by virion PS levels. Lastly, we did not observe a
820 clear role of PS dependent entry in mosquito C6/36 cells, but CHIKV infection in mosquito
821 Aag2 cells was enhanced by viral apoptotic mimicry.

822 References

- 823 1. Gerardin P, Guernier V, Perrau J, Fianu A, Le Roux K, Grivard P, Michault A, de
824 Lamballerie X, Flahault A, Favier F. 2008. Estimating Chikungunya prevalence in La
825 Reunion Island outbreak by serosurveys: two methods for two critical times of the
826 epidemic. *BMC Infect Dis* 8:99.
- 827 2. Moro ML, Gagliotti C, Silvi G, Angelini R, Sambri V, Rezza G, Massimiliani E, Mattivi
828 A, Grilli E, Finarelli AC, Spataro N, Pierro AM, Seyler T, Macini P, Chikungunya Study
829 G. 2010. Chikungunya virus in North-Eastern Italy: a seroprevalence survey. *Am J Trop
830 Med Hyg* 82:508-11.
- 831 3. Brighton SW, Prozesky OW, de la Harpe AL. 1983. Chikungunya virus infection. A
832 retrospective study of 107 cases. *S Afr Med J* 63:313-5.
- 833 4. Sissoko D, Malvy D, Ezzedine K, Renault P, Moschetti F, Ledrans M, Pierre V. 2009.
834 Post-epidemic Chikungunya disease on Reunion Island: course of rheumatic
835 manifestations and associated factors over a 15-month period. *PLoS Negl Trop Dis*
836 3:e389.
- 837 5. Economopoulou A, Dominguez M, Helynck B, Sissoko D, Wichmann O, Quenel P,
838 Germonneau P, Quatresous I. 2009. Atypical Chikungunya virus infections: clinical
839 manifestations, mortality and risk factors for severe disease during the 2005-2006
840 outbreak on Reunion. *Epidemiol Infect* 137:534-41.
- 841 6. Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S. 2007. A single mutation in
842 chikungunya virus affects vector specificity and epidemic potential. *PLoS Pathog* 3:e201.
- 843 7. Agarwal A, Sharma AK, Sukumaran D, Parida M, Dash PK. 2016. Two novel epistatic
844 mutations (E1:K211E and E2:V264A) in structural proteins of Chikungunya virus
845 enhance fitness in *Aedes aegypti*. *Virology* 497:59-68.
- 846 8. Powers AM, Brault AC, Tesh RB, Weaver SC. 2000. Re-emergence of Chikungunya and
847 O'nyong-nyong viruses: evidence for distinct geographical lineages and distant
848 evolutionary relationships. *J Gen Virol* 81:471-9.
- 849 9. Volk SM, Chen R, Tsetsarkin KA, Adams AP, Garcia TI, Sall AA, Nasar F, Schuh AJ,
850 Holmes EC, Higgs S, Maharaj PD, Brault AC, Weaver SC. 2010. Genome-scale
851 phylogenetic analyses of chikungunya virus reveal independent emergences of recent
852 epidemics and various evolutionary rates. *J Virol* 84:6497-504.
- 853 10. Angelini R, Finarelli AC, Angelini P, Po C, Petropulacos K, Silvi G, Macini P, Fortuna
854 C, Venturi G, Magurano F, Fiorentini C, Marchi A, Benedetti E, Bucci P, Boros S, Romi
855 R, Majori G, Ciufolini MG, Nicoletti L, Rezza G, Cassone A. 2007. Chikungunya in
856 north-eastern Italy: a summing up of the outbreak. *Euro Surveill* 12:E071122 2.
- 857 11. Rezza G, Nicoletti L, Angelini R, Romi R, Finarelli AC, Panning M, Cordioli P, Fortuna
858 C, Boros S, Magurano F, Silvi G, Angelini P, Dottori M, Ciufolini MG, Majori GC,
859 Cassone A, group Cs. 2007. Infection with chikungunya virus in Italy: an outbreak in a
860 temperate region. *Lancet* 370:1840-6.
- 861 12. Vega-Rua A, Zouache K, Caro V, Diancourt L, Delaunay P, Grandadam M, Failloux AB.
862 2013. High efficiency of temperate *Aedes albopictus* to transmit chikungunya and dengue
863 viruses in the Southeast of France. *PLoS One* 8:e59716.

- 864 13. Ryan SJ, Carlson CJ, Mordecai EA, Johnson LR. 2019. Global expansion and
865 redistribution of Aedes-borne virus transmission risk with climate change. *PLoS Negl*
866 *Trop Dis* 13:e0007213.
- 867 14. Romi R, Severini F, Toma L. 2006. Cold acclimation and overwintering of female *Aedes*
868 *albopictus* in Roma. *J Am Mosq Control Assoc* 22:149-51.
- 869 15. Fischer D, Thomas SM, Suk JE, Sudre B, Hess A, Tjaden NB, Beierkuhnlein C, Semenza
870 JC. 2013. Climate change effects on Chikungunya transmission in Europe: geospatial
871 analysis of vector's climatic suitability and virus' temperature requirements. *Int J Health*
872 *Geogr* 12:51.
- 873 16. Jose J, Snyder JE, Kuhn RJ. 2009. A structural and functional perspective of alphavirus
874 replication and assembly. *Future Microbiol* 4:837-56.
- 875 17. Simizu B, Yamamoto K, Hashimoto K, Ogata T. 1984. Structural proteins of
876 Chikungunya virus. *J Virol* 51:254-8.
- 877 18. Sun S, Xiang Y, Akahata W, Holdaway H, Pal P, Zhang X, Diamond MS, Nabel GJ,
878 Rossmann MG. 2013. Structural analyses at pseudo atomic resolution of Chikungunya
879 virus and antibodies show mechanisms of neutralization. *Elife* 2:e00435.
- 880 19. Voss JE, Vaney MC, Duquerroy S, Vonrhein C, Girard-Blanc C, Crublet E, Thompson
881 A, Bricogne G, Rey FA. 2010. Glycoprotein organization of Chikungunya virus particles
882 revealed by X-ray crystallography. *Nature* 468:709-12.
- 883 20. Kielian M. 1995. Membrane fusion and the alphavirus life cycle. *Adv Virus Res* 45:113-
884 51.
- 885 21. Lu YE, Kielian M. 2000. Semliki forest virus budding: assay, mechanisms, and
886 cholesterol requirement. *J Virol* 74:7708-19.
- 887 22. Zhang R, Kim AS, Fox JM, Nair S, Basore K, Klimstra WB, Rimkunas R, Fong RH, Lin
888 H, Poddar S, Crowe JE, Jr., Doranz BJ, Fremont DH, Diamond MS. 2018. Mxra8 is a
889 receptor for multiple arthritogenic alphaviruses. *Nature* 557:570-574.
- 890 23. Tanaka A, Tumkosit U, Nakamura S, Motooka D, Kishishita N, Priengprom T, Sa-
891 Ngasang A, Kinoshita T, Takeda N, Maeda Y. 2017. Genome-Wide Screening Uncovers
892 the Significance of N-Sulfation of Heparan Sulfate as a Host Cell Factor for
893 Chikungunya Virus Infection. *J Virol* 91.
- 894 24. Weber C, Berberich E, von Rhein C, Henss L, Hildt E, Schnierle BS. 2017. Identification
895 of Functional Determinants in the Chikungunya Virus E2 Protein. *PLoS Negl Trop Dis*
896 11:e0005318.
- 897 25. Sahoo B, Chowdary TK. 2019. Conformational changes in Chikungunya virus E2 protein
898 upon heparan sulfate receptor binding explain mechanism of E2-E1 dissociation during
899 viral entry. *Biosci Rep* 39.
- 900 26. McAllister N, Liu Y, Silva LM, Lentscher AJ, Chai W, Wu N, Griswold KA,
901 Raghunathan K, Vang L, Alexander J, Warfield KL, Diamond MS, Feizi T, Silva LA,
902 Dermody TS. 2020. Chikungunya Virus Strains from Each Genetic Clade Bind Sulfated
903 Glycosaminoglycans as Attachment Factors. *J Virol* 94.
- 904 27. Prado Acosta M, Geoghegan EM, Lepenies B, Ruzal S, Kielian M, Martinez MG. 2019.
905 Surface (S) Layer Proteins of *Lactobacillus acidophilus* Block Virus Infection via DC-
906 SIGN Interaction. *Front Microbiol* 10:810.
- 907 28. Bucardo F, Reyes Y, Morales M, Briceno R, Gonzalez F, Lundkvist A, Svensson L,
908 Nordgren J. 2020. Genetic polymorphisms in DC-SIGN, TLR3 and TNFa genes and the

- 909 Lewis-negative phenotype are associated with Chikungunya infection and disease in
910 Nicaragua. *J Infect Dis* doi:10.1093/infdis/jiaa364.
- 911 29. Wintachai P, Wikan N, Kuadkitkan A, Jaimipuk T, Ubol S, Pulmanausahakul R,
912 Auewarakul P, Kasinrerak W, Weng WY, Panyasrivanit M, Paemanee A, Kittisenachai S,
913 Roytrakul S, Smith DR. 2012. Identification of prohibitin as a Chikungunya virus
914 receptor protein. *J Med Virol* 84:1757-70.
- 915 30. Meertens L, Carnec X, Lecoin MP, Ramdasi R, Guivel-Benhassine F, Lew E, Lemke G,
916 Schwartz O, Amara A. 2012. The TIM and TAM families of phosphatidylserine receptors
917 mediate dengue virus entry. *Cell Host Microbe* 12:544-57.
- 918 31. Moller-Tank S, Kondratowicz AS, Davey RA, Rennert PD, Maury W. 2013. Role of the
919 phosphatidylserine receptor TIM-1 in enveloped-virus entry. *J Virol* 87:8327-41.
- 920 32. Kirui J, Abidine Y, Lenman A, Islam K, Gwon YD, Lasswitz L, Evander M, Bally M,
921 Gerold G. 2021. The Phosphatidylserine Receptor TIM-1 Enhances Authentic
922 Chikungunya Virus Cell Entry. *Cells* 10.
- 923 33. Carnec X, Meertens L, Dejarnac O, Perera-Lecoin M, Hafirassou ML, Kitaura J, Ramdasi
924 R, Schwartz O, Amara A. 2016. The Phosphatidylserine and Phosphatidylethanolamine
925 Receptor CD300a Binds Dengue Virus and Enhances Infection. *J Virol* 90:92-102.
- 926 34. Zhang R, Earnest JT, Kim AS, Winkler ES, Desai P, Adams LJ, Hu G, Bullock C, Gold
927 B, Cherry S, Diamond MS. 2019. Expression of the Mxra8 Receptor Promotes
928 Alphavirus Infection and Pathogenesis in Mice and *Drosophila*. *Cell Rep* 28:2647-2658
929 e5.
- 930 35. Kay JG, Fairn GD. 2019. Distribution, dynamics and functional roles of
931 phosphatidylserine within the cell. *Cell Commun Signal* 17:126.
- 932 36. van Meer G, Voelker DR, Feigenson GW. 2008. Membrane lipids: where they are and
933 how they behave. *Nat Rev Mol Cell Biol* 9:112-24.
- 934 37. Takatsu H, Tanaka G, Segawa K, Suzuki J, Nagata S, Nakayama K, Shin HW. 2014.
935 Phospholipid flippase activities and substrate specificities of human type IV P-type
936 ATPases localized to the plasma membrane. *J Biol Chem* 289:33543-56.
- 937 38. Papadopulos A, Vehring S, Lopez-Montero I, Kutschenko L, Stockl M, Devaux PF,
938 Kozlov M, Pomorski T, Herrmann A. 2007. Flippase activity detected with unlabeled
939 lipids by shape changes of giant unilamellar vesicles. *J Biol Chem* 282:15559-68.
- 940 39. Andersen JP, Vestergaard AL, Mikkelsen SA, Mogensen LS, Chalal M, Molday RS.
941 2016. P4-ATPases as Phospholipid Flippases-Structure, Function, and Enigmas. *Front*
942 *Physiol* 7:275.
- 943 40. Huang W, Liao G, Baker GM, Wang Y, Lau R, Paderu P, Perlin DS, Xue C. 2016. Lipid
944 Flippase Subunit Cdc50 Mediates Drug Resistance and Virulence in *Cryptococcus*
945 *neoformans*. *mBio* 7.
- 946 41. Yang F, Huang Y, Chen X, Liu L, Liao D, Zhang H, Huang G, Liu W, Zhu X, Wang W,
947 Lobo CA, Yazdanbakhsh K, An X, Ju Z. 2019. Deletion of a flippase subunit Tmem30a
948 in hematopoietic cells impairs mouse fetal liver erythropoiesis. *Haematologica* 104:1984-
949 1994.
- 950 42. Segawa K, Kurata S, Yanagihashi Y, Brummelkamp TR, Matsuda F, Nagata S. 2014.
951 Caspase-mediated cleavage of phospholipid flippase for apoptotic phosphatidylserine
952 exposure. *Science* 344:1164-8.

- 953 43. Suzuki J, Imanishi E, Nagata S. 2016. Xkr8 phospholipid scrambling complex in
954 apoptotic phosphatidylserine exposure. *Proc Natl Acad Sci U S A* 113:9509-14.
- 955 44. Bricogne C, Fine M, Pereira PM, Sung J, Tijani M, Wang Y, Henriques R, Collins MK,
956 Hilgemann DW. 2019. TMEM16F activation by Ca(2+) triggers plasma membrane
957 expansion and directs PD-1 trafficking. *Sci Rep* 9:619.
- 958 45. Jemielity S, Wang JJ, Chan YK, Ahmed AA, Li W, Monahan S, Bu X, Farzan M,
959 Freeman GJ, Umetsu DT, Dekruyff RH, Choe H. 2013. TIM-family proteins promote
960 infection of multiple enveloped viruses through virion-associated phosphatidylserine.
961 *PLoS Pathog* 9:e1003232.
- 962 46. Richard AS, Zhang A, Park SJ, Farzan M, Zong M, Choe H. 2015. Virion-associated
963 phosphatidylethanolamine promotes TIM1-mediated infection by Ebola, dengue, and
964 West Nile viruses. *Proc Natl Acad Sci U S A* 112:14682-7.
- 965 47. Brouillette RB, Phillips EK, Patel R, Mahauad-Fernandez W, Moller-Tank S, Rogers KJ,
966 Dillard JA, Cooney AL, Martinez-Sobrido L, Okeoma C, Maury W. 2018. TIM-1
967 Mediates Dystroglycan-Independent Entry of Lassa Virus. *J Virol* 92.
- 968 48. Zhang L, Richard AS, Jackson CB, Ojha A, Choe H. 2020. Phosphatidylethanolamine
969 and Phosphatidylserine Synergize To Enhance GAS6/AXL-Mediated Virus Infection and
970 Efferocytosis. *J Virol* 95.
- 971 49. Acciani MD, Lay Mendoza MF, Havranek KE, Duncan AM, Iyer H, Linn OL, Brindley
972 MA. 2021. Ebola virus requires phosphatidylserine scrambling activity for efficient
973 budding and optimal infectivity. *J Virol* doi:10.1128/JVI.01165-21:JVI0116521.
- 974 50. Dejarnac O, Hafirassou ML, Chazal M, Versapuech M, Gaillard J, Perera-Lecoin M,
975 Umana-Diaz C, Bonnet-Madin L, Carnec X, Tinevez JY, Delaugerre C, Schwartz O,
976 Roingard P, Jouvenet N, Berlioz-Torrent C, Meertens L, Amara A. 2018. TIM-1
977 Ubiquitination Mediates Dengue Virus Entry. *Cell Rep* 23:1779-1793.
- 978 51. Amara A, Mercer J. 2015. Viral apoptotic mimicry. *Nat Rev Microbiol* 13:461-9.
- 979 52. Lay Mendoza MF, Acciani MD, Levit CN, Santa Maria C, Brindley MA. 2020.
980 Monitoring Viral Entry in Real-Time Using a Luciferase Recombinant Vesicular
981 Stomatitis Virus Producing SARS-CoV-2, EBOV, LASV, CHIKV, and VSV
982 Glycoproteins. *Viruses* 12.
- 983 53. Cao W, Henry MD, Borrow P, Yamada H, Elder JH, Ravkov EV, Nichol ST, Compans
984 RW, Campbell KP, Oldstone MB. 1998. Identification of alpha-dystroglycan as a
985 receptor for lymphocytic choriomeningitis virus and Lassa fever virus. *Science* 282:2079-
986 81.
- 987 54. Jae LT, Raaben M, Riemersma M, van Beusekom E, Blomen VA, Velds A, Kerkhoven
988 RM, Carette JE, Topaloglu H, Meinecke P, Wessels MW, Lefeber DJ, Whelan SP, van
989 Bokhoven H, Brummelkamp TR. 2013. Deciphering the glycosylome of
990 dystroglycanopathies using haploid screens for lassa virus entry. *Science* 340:479-83.
- 991 55. Kunz S, Rojek JM, Kanagawa M, Spiropoulou CF, Barresi R, Campbell KP, Oldstone
992 MB. 2005. Posttranslational modification of alpha-dystroglycan, the cellular receptor for
993 arenaviruses, by the glycosyltransferase LARGE is critical for virus binding. *J Virol*
994 79:14282-96.
- 995 56. Krejbich-Trotot P, Denizot M, Hoarau JJ, Jaffar-Bandjee MC, Das T, Gasque P. 2011.
996 Chikungunya virus mobilizes the apoptotic machinery to invade host cell defenses.
997 *FASEB J* 25:314-25.

- 998 57. Shimojima M, Takada A, Ebihara H, Neumann G, Fujioka K, Irimura T, Jones S,
999 Feldmann H, Kawaoka Y. 2006. Tyro3 family-mediated cell entry of Ebola and Marburg
1000 viruses. *J Virol* 80:10109-16.
- 1001 58. Fast P. 1964. *Insect lipids: A review*. Entomological Society of Canada, Ottawa.
- 1002 59. Luukkonen A, Brummer-Korvenkontio M, Renkonen O. 1973. Lipids of cultured
1003 mosquito cells (*Aedes albopictus*). Comparison with cultured mammalian fibroblasts
1004 (BHK 21 cells). *Biochim Biophys Acta* 326:256-61.
- 1005 60. Shiomi A, Nagao K, Yokota N, Tsuchiya M, Kato U, Juni N, Hara Y, Mori MX, Mori Y,
1006 Ui-Tei K, Murate M, Kobayashi T, Nishino Y, Miyazawa A, Yamamoto A, Suzuki R,
1007 Kaufmann S, Tanaka M, Tatsumi K, Nakabe K, Shintaku H, Yesylevsky S, Bogdanov M,
1008 Umeda M. 2021. Extreme deformability of insect cell membranes is governed by
1009 phospholipid scrambling. *Cell Rep* 35:109219.
- 1010 61. Nanbo A, Maruyama J, Imai M, Ujie M, Fujioka Y, Nishide S, Takada A, Ohba Y,
1011 Kawaoka Y. 2018. Ebola virus requires a host scramblase for externalization of
1012 phosphatidylserine on the surface of viral particles. *PLoS Pathog* 14:e1006848.
- 1013 62. Yin P, Kielian M. 2021. BHK-21 Cell Clones Differ in Chikungunya Virus Infection and
1014 MXRA8 Receptor Expression. *Viruses* 13.
- 1015 63. Basore K, Kim AS, Nelson CA, Zhang R, Smith BK, Uranga C, Vang L, Cheng M, Gross
1016 ML, Smith J, Diamond MS, Fremont DH. 2019. Cryo-EM Structure of Chikungunya
1017 Virus in Complex with the Mxra8 Receptor. *Cell* 177:1725-1737 e16.
- 1018 64. Song H, Zhao Z, Chai Y, Jin X, Li C, Yuan F, Liu S, Gao Z, Wang H, Song J, Vazquez
1019 L, Zhang Y, Tan S, Morel CM, Yan J, Shi Y, Qi J, Gao F, Gao GF. 2019. Molecular
1020 Basis of Arthritogenic Alphavirus Receptor MXRA8 Binding to Chikungunya Virus
1021 Envelope Protein. *Cell* 177:1714-1724 e12.
- 1022 65. Silva LA, Khomandiak S, Ashbrook AW, Weller R, Heise MT, Morrison TE, Dermody
1023 TS. 2014. A single-amino-acid polymorphism in Chikungunya virus E2 glycoprotein
1024 influences glycosaminoglycan utilization. *J Virol* 88:2385-97.
- 1025 66. Ashbrook AW, Burrack KS, Silva LA, Montgomery SA, Heise MT, Morrison TE,
1026 Dermody TS. 2014. Residue 82 of the Chikungunya virus E2 attachment protein
1027 modulates viral dissemination and arthritis in mice. *J Virol* 88:12180-92.
- 1028 67. Hawman DW, Fox JM, Ashbrook AW, May NA, Schroeder KMS, Torres RM, Crowe
1029 JE, Jr., Dermody TS, Diamond MS, Morrison TE. 2016. Pathogenic Chikungunya Virus
1030 Evades B Cell Responses to Establish Persistence. *Cell Rep* 16:1326-1338.
- 1031 68. Bernard E, Hamel R, Neyret A, Ekcharyawat P, Moles JP, Simmons G, Chazal N,
1032 Despres P, Misse D, Briant L. 2015. Human keratinocytes restrict chikungunya virus
1033 replication at a post-fusion step. *Virology* 476:1-10.
- 1034 69. Bauer T, Zagorska A, Jurkin J, Yasmin N, Koffel R, Richter S, Gesslbauer B, Lemke G,
1035 Strobl H. 2012. Identification of Axl as a downstream effector of TGF-beta1 during
1036 Langerhans cell differentiation and epidermal homeostasis. *J Exp Med* 209:2033-47.
- 1037 70. Freeman GJ, Casasnovas JM, Umetsu DT, DeKruyff RH. 2010. TIM genes: a family of
1038 cell surface phosphatidylserine receptors that regulate innate and adaptive immunity.
1039 *Immunol Rev* 235:172-89.
- 1040 71. Wang Q, Imamura R, Motani K, Kushiyama H, Nagata S, Suda T. 2013. Pyroptotic cells
1041 externalize eat-me and release find-me signals and are efficiently engulfed by
1042 macrophages. *Int Immunol* 25:363-72.

- 1043 72. Pietkiewicz S, Schmidt JH, Lavrik IN. 2015. Quantification of apoptosis and necroptosis
1044 at the single cell level by a combination of Imaging Flow Cytometry with classical
1045 Annexin V/propidium iodide staining. *J Immunol Methods* 423:99-103.
- 1046 73. Sourisseau M, Schilte C, Casartelli N, Trouillet C, Guivel-Benhassine F, Rudnicka D,
1047 Sol-Foulon N, Le Roux K, Prevost MC, Fsihi H, Frenkiel MP, Blanchet F, Afonso PV,
1048 Ceccaldi PE, Ozden S, Gessain A, Schuffenecker I, Verhasselt B, Zamborlini A, Saib A,
1049 Rey FA, Arenzana-Seisdedos F, Despres P, Michault A, Albert ML, Schwartz O. 2007.
1050 Characterization of reemerging chikungunya virus. *PLoS Pathog* 3:e89.
- 1051 74. Young AR, Locke MC, Cook LE, Hiller BE, Zhang R, Hedberg ML, Monte KJ, Veis DJ,
1052 Diamond MS, Lenschow DJ. 2019. Dermal and muscle fibroblasts and skeletal myofibers
1053 survive chikungunya virus infection and harbor persistent RNA. *PLoS Pathog*
1054 15:e1007993.
- 1055 75. Lentscher AJ, McCarthy MK, May NA, Davenport BJ, Montgomery SA, Raghunathan
1056 K, McAllister N, Silva LA, Morrison TE, Dermody TS. 2020. Chikungunya virus
1057 replication in skeletal muscle cells is required for disease development. *J Clin Invest*
1058 130:1466-1478.
- 1059 76. Moser LA, Boylan BT, Moreira FR, Myers LJ, Svenson EL, Fedorova NB, Pickett BE,
1060 Bernard KA. 2018. Growth and adaptation of Zika virus in mammalian and mosquito
1061 cells. *PLoS Negl Trop Dis* 12:e0006880.
- 1062 77. Reyes-Ruiz JM, Osuna-Ramos JF, Bautista-Carbajal P, Jaworski E, Soto-Acosta R,
1063 Cervantes-Salazar M, Angel-Ambrocio AH, Castillo-Munguia JP, Chavez-Munguia B,
1064 De Nova-Ocampo M, Routh A, Del Angel RM, Salas-Benito JS. 2019. Mosquito cells
1065 persistently infected with dengue virus produce viral particles with host-dependent
1066 replication. *Virology* 531:1-18.
- 1067 78. Hafer A, Whittlesey R, Brown DT, Hernandez R. 2009. Differential incorporation of
1068 cholesterol by Sindbis virus grown in mammalian or insect cells. *J Virol* 83:9113-21.
- 1069 79. Carro AC, Damonte EB. 2013. Requirement of cholesterol in the viral envelope for
1070 dengue virus infection. *Virus Res* 174:78-87.
- 1071 80. Hanna SL, Pierson TC, Sanchez MD, Ahmed AA, Murtadha MM, Doms RW. 2005. N-
1072 linked glycosylation of west nile virus envelope proteins influences particle assembly and
1073 infectivity. *J Virol* 79:13262-74.
- 1074 81. Lim PY, Louie KL, Styer LM, Shi PY, Bernard KA. 2010. Viral pathogenesis in mice is
1075 similar for West Nile virus derived from mosquito and mammalian cells. *Virology*
1076 400:93-103.
- 1077 82. Boylan BT, Moreira FR, Carlson TW, Bernard KA. 2017. Mosquito cell-derived West
1078 Nile virus replicon particles mimic arbovirus inoculum and have reduced spread in mice.
1079 *PLoS Negl Trop Dis* 11:e0005394.
- 1080 83. Acharya D, Paul AM, Anderson JF, Huang F, Bai F. 2015. Loss of Glycosaminoglycan
1081 Receptor Binding after Mosquito Cell Passage Reduces Chikungunya Virus Infectivity.
1082 *PLoS Negl Trop Dis* 9:e0004139.
- 1083 84. Dunbar CA, Rayaprolu V, Wang JC, Brown CJ, Leishman E, Jones-Burrage S, Trinidad
1084 JC, Bradshaw HB, Clemmer DE, Mukhopadhyay S, Jarrold MF. 2019. Dissecting the
1085 Components of Sindbis Virus from Arthropod and Vertebrate Hosts: Implications for
1086 Infectivity Differences. *ACS Infect Dis* 5:892-902.

- 1087 85. van den Eijnde SM, Boshart L, Baehrecke EH, De Zeeuw CI, Reutelingsperger CP,
1088 Vermeij-Keers C. 1998. Cell surface exposure of phosphatidylserine during apoptosis is
1089 phylogenetically conserved. *Apoptosis* 3:9-16.
- 1090 86. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. 2013. Genome engineering
1091 using the CRISPR-Cas9 system. *Nat Protoc* 8:2281-2308.
- 1092 87. Ramakrishnan MA. 2016. Determination of 50% endpoint titer using a simple formula.
1093 *World J Virol* 5:85-6.
- 1094 88. McCarthy MK, Davenport BJ, Reynoso GV, Lucas ED, May NA, Elmore SA, Tamburini
1095 BA, Hickman HD, Morrison TE. 2018. Chikungunya virus impairs draining lymph node
1096 function by inhibiting HEV-mediated lymphocyte recruitment. *JCI Insight* 3.
- 1097




Fig 1




Fig 2




Fig 3




Fig 4





Fig 5






Fig 7




Fig 8